Navigation Links
Access and Somanta Announce Data to be Presented on Angiolix at,ASCO Oncology Conference

Pre-clinical Data Suggests Angiolix Can Inhibit Breast Cancer Growth By 75%

DALLAS and IRVINE, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (Bulletin Board: ACCP) and Somanta Pharmaceuticals, Inc. (Bulletin Board: SMPM) announced today that a scientific abstract outlining new preclinical efficacy data for Somanta's Angiolix has been selected for publication in the Proceedings of the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, IL, June 1-5, 2007. The data, in a study conducted using mouse models, shows that Angiolix has been able to achieve more than 75% growth inhibition of human breast cancer growing as xenografts in mouse.

ASCO's annual meeting is the world's premier oncology conference providing information on the latest developments in cancer treatment. As previously announced Access and Somanta have signed a definitive merger agreement for Access to acquire Somanta as a step in the creation of a combined company with a broad cancer-focused portfolio in which Angiolix will be a major program.

Angiolix is a humanized monoclonal antibody that recognizes a migrating adhesion molecule called Lactadherin. Somanta's recent data suggests that tumor cells express Lactadherin which is a factor in the growth of tumor vasculature. Several existing or potential anti-cancer drugs (such as Avastin) seek to block tumor vascularization by blocking a signaling protein know as vascular endothelial growth factor (VEGF). The binding of Angiolix to Lactadherin is thought to cause a VEGF-independent integrin receptor signaling cascade that blocks vascular endothelial cell proliferation. Due to its ability to neutralize Lactadherin-integrin receptor binding, Angiolix may be able to specifically target breast cancer cells and thereby cause tumor suppression by blocking the growth of tumor vasculature.

Dr. Agamemnon Epenetos, CEO of Som anta and a coauthor of the Angiolix abstract commented, "We are pleased to be presenting data on Angiolix at this year's ASCO conference. The preclinical data shows exciting results in a widely used model of breast cancer. By targeting tumor vascularization, Angiolix has the potential to cause tumor regression and prevent recurrence of growth."

"On behalf of both companies we are grateful for the opportunity to present data at this year's ASCO Conference," added Stephen R. Seiler, Access' President and CEO. "Recent studies indicate that Angiolix has the potential to choke off blood flow to breast tumors, which inherently causes tumor regression."

About Access

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer and MuGard(TM) for the management of patients with mucositis. The Company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com .

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties, including statements relating to the efficacy and method of action of Angiolix, the value of our products in the market, our ability to achieve clinical and commercial success, our ability to successfully develop marketed products and the ability to obtain the approvals of Somanta's stockholders, to obtain or meet the closing conditions in the merger agreement, including applicable regulatory and tax requirements, and to otherwise complete the m erger in a timely manner. These statements are subject to numerous risks, including but not limited to the risks detailed in Access' and Somanta's Annual Report on Form 10-KSB and other reports filed by Access and Somanta with the Securities and Exchange Commission.

CONTACT: Company, Stephen B. Thompson, Vice President and Chief FinancialOfficer of Access Pharmaceuticals, Inc., +1-214-905-5100; Investors, DonaldC. Weinberger or Alisa Steinberg of Wolfe Axelrod Weinberger Assoc. LLC,+1-212-370-4500, for Access Pharmaceuticals, Inc.; or Andrew Hellman ofCEOcast, Inc., +1-212-732-4300, for Access Pharmaceuticals, Inc.

Web site: http://www.accesspharma.com/

Ticker Symbol: (:ACCP),(:SMPM)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. PromegaExpress Expands Easy Access to Products with New Cabinet
2. Access Pharmaceuticals Announces Poster Presentations on ProLindac at the American Association for Cancer Research 2007 Annual Meeting
3. Somanta Announces the Presentation of Alchemix Data at The American Association for Cancer Research Annual Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):